Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT on Warner Chilcott

Related WCRX
Actavis, Warner Chilcott Receive FTC Clearance for Actavis' Proposed Acquisition of Warner Chilcott
Top 4 Mid-Cap Stocks In The Drug Manufacturers-Other Industry With The Highest Profit Margin

In a report published Monday, Jefferies & Company reiterated its Buy rating on Warner Chilcott (NASDAQ: WCRX), but lowered its price target from $19.00 to $15.00.

Jefferies noted, “WCRX blew away 3Q EPS and again reduced OpEx/raised EPS guidance. Mgmt has done a great job cutting costs, though it's unclear how much deeper it can go. 2013 will likely be challenging given revenue declines, but management continues to highlight its secretive pipeline. Further, while no BD activity has materialized, mgmt's commentary around Derm expansion is intriguing. We lower PT to $15 to reflect payment of $4 special dividend.”

Warner Chilcott closed on Friday at $11.67.

Latest Ratings for WCRX

Jul 2013Leerink SwannUpgradesMarket PerformOutperform
Jun 2013JefferiesDowngradesBuyHold
May 2013Leerink SwannDowngradesOutperformMarket Perform

View More Analyst Ratings for WCRX
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings


Related Articles (WCRX)

View Comments and Join the Discussion!

Partner Center